



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s) : Stockert, et al.
Serial No : Divisional of 09/751,798
Filed : Herewith
For : ANTIBODIES WHICH BIND TO NY-ESO-1 CANCER ASSOCIATED PROTEINS, USES THEREOF, TRUNCATED FORMS OF NY-ESO-1 AND HLA BINDING PROTEINS DERIVED THEREFROM
Art Unit : To Be Assigned
Examiner : To Be Assigned

December 17, 2001

Hon. Commissioner of Patents
and Trademarks
Washington, D.C. 20231

PRELIMINARY AMENDMENT

Prior to examination, please amend this application as follows:

IN THE TITLE

Cancel the current title and replace by -- Isolated Nucleic Acid Molecules Encoding ESO-1 Peptides And Uses Thereof--.

IN THE SPECIFICATION

Page 1, line 1: change "APPLICATION" to --APPLICATIONS--.

Page 4, lines 26-28: delete from "and" through "All three" and replace by --Both--.

Page 7, line 9: change "Fcγ" to --Fcγ"--.

Page 16, line 14: change "755" to --752-- and "543" to --540";

line 16: change "151" to --159--.

Page 17, line: delete second ","; after "also, figure 3" and --(SEQ ID NO: 8)--

line 20: prior to "CACACAAGC", insert --5'--.

Page 28, line 19: change "complementary" to --complementarity--

line 20: after regions, add -i.e., the--;

change "CDRS" to --CDRs--.

IN THE CLAIMS

Cancel claims 1-21 without prejudice.

Add claims 22-31 which follow:

Claim 22: An isolated nucleic acid molecule which consists of a nucleotide sequence that encodes a tumor rejection antigen, the amino acid sequence of which consists of an amino acid sequence set forth in NY-ESO-1, SEQ ID NO: 1.

Claim 23: The isolated nucleic acid molecule of claim 1, consisting of a nucleotide sequence which encodes the amino acid sequence set forth in SEQ ID NO: 4, SEQ ID NO: 5 or SEQ ID NO: 6.

Claim 24: An expression vector comprising the isolated nucleic acid molecule of claim 22, operably linked to a promoter.

Claim 25: An expression vector comprising the isolated nucleic acid molecule of claim 23, operably linked to a promoter.

Claim 26: The expression vector of claim 24, wherein said expression vector is adenovirus based.

Claim 27: The expression vector of claim 25, wherein said expression vector is adenovirus based.

Claim 28: Eukaryotic cell transformed or transfected with the expression vector of claim 24.

Claim 29: Eukaryotic cell transformed or transfected with the expression vector of claim 25.

Claim 31: Eukaryotic cell transformed or transfected with the expression vector of claim 27.

• as pages 24-26 of the specification.

FULBRIGHT & JAWORSKI, L.L.P.

Norman D. Hanson, Esq.
Registration No. 30,946

666 Fifth Avenue
New York, New York 10103-3198
Telephone: 212-318-3168
Telecopier: 212-318-3400